SC
PCVX icon

SummitTX Capital’s Vaxcyte PCVX Stock Holding History

SummitTX Capital’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.33M Sell
57,355
-17,487
-23% -$950K 0.09% 247
2026
Q1 		$4.35M Buy
74,842
+59,973
+403% +$3.26M 0.14% 175
2025
Q4 		$686K Buy
14,869
+8,210
+123% +$367K 0.02% 480
2025
Q3 		$240K Buy
+6,659
New +$221K 0.01% 673
2025
Q2 		– Sell
-93,071
Closed -$3.51M – 960
2025
Q1 		$3.51M Buy
+93,071
New +$7.44M 0.15% 165

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

SummitTX Capital's PCVX Position: Q2 2026 in Review

SummitTX Capital reduced its Vaxcyte (PCVX) stake by 23% in Q2 2026, selling an estimated $950K and leaving 57,355 shares worth $3.33M. The position accounts for 0.09% of the portfolio, ranked #247.

SummitTX Capital first reported a position in PCVX in Q1 2025 and has held it in 5 quarters since. The position peaked at $4.35M in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • SummitTX Capital held 57,355 shares of Vaxcyte worth $3.33M as of Q2 2026.
  • SummitTX Capital sold 17,487 Vaxcyte shares in Q2 2026, an estimated $950K.
  • Vaxcyte made up 0.09% of SummitTX Capital's portfolio in Q2 2026, its #247 holding.
  • SummitTX Capital first reported a position in Vaxcyte in Q1 2025 and has held it in 5 quarters since.
  • SummitTX Capital's Vaxcyte position peaked at $4.35M in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.